REMARKS

In response to the examiner's requirement for restriction, the applicant's elect Group I, consisting of Claims 44-54 and 63-64. The claims of Group II and Group III have been cancelled without prejudice to filing one or more divisional applications.

However, claims 44-54 and 63-64 have also been cancelled, and replaced by new claims 65-82.

As a general comment, new claims 65-82 have been restricted to refer more clearly to the object of the invention, i.e. an antibody fragment binding to GPIb. Thus a number of general claims relating to cell lines and whole antibodies which were part of group I have been omitted, leaving only the claims to the specific antibody and cell line producing this antibody specifically described in the application.

Group I as identified by the Examiner included claims 44-54 and 63-64. Claims 65 to 71 correspond to former claim 54 and specific embodiments thereof described in the application.

New claims 72-79 correspond to former claims 48-49. New claim 80 corresponds to former claim 52, but instead of reciting the name of the antibody, it now recites the name of the cell line producing the antibody (as this is a clearer reference). New claim 81 corresponds to former claim 44, but limited to the specific cell line recited in that claim.

New claim 82 corresponds to former claim 53, except that it now relates to an antibody fragment instead of an antibody.

Further action by the examiner is awaited.

September 24, 2004

Respectfully submitted,

William M. Lee, Jr.

Registration No. 26,935 Barnes & Thornburg

P.O. Box 2786

Chicago, Illinois 60690-2786 (312) 214-4800

(312) 759-5646 (fax)